Stock Analysis
WDB coco (TSE:7079) Full Year 2024 Results
Key Financial Results
- Revenue: JP¥4.60b (up 13% from FY 2023).
- Net income: JP¥857.0m (up 15% from FY 2023).
- Profit margin: 19% (in line with FY 2023).
- EPS: JP¥357 (up from JP¥311 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
WDB coco Earnings Insights
Looking ahead, revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia.
Performance of the market in Japan.
The company's shares are down 18% from a week ago.
Risk Analysis
You still need to take note of risks, for example - WDB coco has 2 warning signs (and 1 which doesn't sit too well with us) we think you should know about.
Valuation is complex, but we're helping make it simple.
Find out whether WDB coco is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:7079
WDB coco
Provides contract services to pharmaceutical companies in Japan.
Flawless balance sheet and undervalued.
